Acer Therapeutics (ACER) Announces Quarterly Earnings Results
Acer Therapeutics (NASDAQ:ACER) issued its earnings results on Friday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.10, MarketWatch Earnings reports.
ACER stock traded up $0.29 during midday trading on Friday, hitting $24.91. The company had a trading volume of 7,116 shares, compared to its average volume of 29,773. Acer Therapeutics has a 52 week low of $11.36 and a 52 week high of $34.10. The company has a market capitalization of $242.20 million, a P/E ratio of -6.49 and a beta of 2.75.
Several analysts have issued reports on the company. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 29th. BidaskClub downgraded Acer Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Raymond James upgraded Acer Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $31.00 to $46.00 in a research report on Friday, August 17th. Zacks Investment Research downgraded Acer Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Finally, William Blair reiterated an “outperform” rating on shares of Acer Therapeutics in a research report on Tuesday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Acer Therapeutics currently has a consensus rating of “Buy” and an average target price of $48.00.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease.
Featured Article: What factors cause inflation to rise?
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.